跳至主要内容
临床试验/NCT02393937
NCT02393937已完成3 期

A Multi-center, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Metronidazole Gel 1%, to Metrogel® (Metronidazole Gel) 1% in the Treatment of Rosacea

bioRASI, LLC0 个研究点目标入组 963 人开始时间: 2015年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
bioRASI, LLC
入组人数
963
主要终点
To compare the test and reference products of metronidazole topical gel 1% with regard to the mean percent change from Baseline of the inflammatory lesion counts of rosacea.

研究概览

简要总结

The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female subjects with at least 18 years of age;
  • Read and signed ICF;
  • Clinical Diagnosis of Rosacea;

排除标准

  • Females who are pregnant, lactating or of childbearing potential who are not using or do not agree to use an acceptable form of contraception;
  • Any skin condition that would interfere with treatment of rosacea
  • Use of prohibited medications

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo Gel once daily for 70 days.

干预措施: Placebo Gel (Drug)

结局指标

主要结局

To compare the test and reference products of metronidazole topical gel 1% with regard to the mean percent change from Baseline of the inflammatory lesion counts of rosacea.

时间窗: 70 Days

次要结局

  • To compare the test and reference product of metronidazole topical gel 1% with regard to the Investigator's Global Evaluation (IGE) of disease severity(70 Days)

研究者

发起方
bioRASI, LLC
申办方类型
Industry
责任方
Sponsor

相似试验